冬凌草乙素联合卡培他滨对乳腺癌细胞增殖和侵袭的影响

Effects of Rubescene B Combined with Capecitabine on Proliferation and Invasion of Breast Cancer Cells

【目的】 探讨冬凌草乙素联合卡培他滨对乳腺癌细胞增殖和侵袭的影响。【方法】 构建乳腺癌4T1细胞系,按加入药物不同分为4组:冬凌草乙素组(A组),卡培他滨组(B组),冬凌草乙素+卡培他滨组(C组)和空白对照组(D组)。采用MTT法测定各组乳腺癌4T1细胞株的增殖抑制率。采用Transwell小室法测定各组药物对乳腺癌4T1细胞株侵袭能力的影响。采用RT-PCR法检测乳腺癌4T1细胞株β-catenin、cyclin D1、c-myc的mRNA表达。【结果】 A组、B组、C组均对乳腺癌4T1细胞株的增殖具有抑制作用,其中C组的抑制作用最强,高于其余三组(P<0.05)。A组、B组及C组均对乳腺癌4T1细胞株的侵袭力具有抑制作用,C组处理后,细胞株的侵袭力最弱,低于其余三组(P<0.05)。A组和B组的β-catenin、cyclin D1、c-myc的mRNA表达明显下调(P<0.05)。【结论】 冬凌草乙素联合卡培他滨能明显抑制乳腺癌4T1细胞的增殖,并抑制其侵袭能力,作用机制与调控Wnt/β-catenin信号通路有关。

【Objective】 To investigate the effect of rubescene B combined with capecitabine on proliferation and invasion of breast cancer cells.【Method】 The breast cancer cell line 4T1was established and randomly divided into four groups: rubescene B group (group A), capecitabine group (group B), rubescene B + capecitabine group (group C) and blank control group (group D). MTT assay was used to detect the increment inhibition rate of breast cancer cell line 4T1 in each group. The effect of drugs on invasive ability of breast cancer cell line 4T1 was determined by Transwell chamber assay. RT-PCR method was used to detect the expression of beta-catenin, cyclin D1 and c-myc mRNA in breast cancer cell line 4T1. 【Results】 Treatment in group A, B and C all inhibited the proliferation of breast cancer 4T1 cells, and group C had the strongest inhibition, which was higher than the other groups (P<0.05). The invasiveness of breast cancer 4T1 cells was inhibited in group A, group B and group C. The invasiveness of breast cancer 4T1 cells in group C was the weakest, which was lower than that of the other three groups (P<0.05). The expression of beta-catenin, cyclin D1 and c-myc was significantly down-regulated by rubescene B combined with capecitabine (P<0.05). 【Conclusions】 Rubescene B combined with capecitabine can significantly inhibit the proliferation of breast cancer 4T1 cells, and inhibit cell invasion, which is related to the suppressing the Wnt/β-catenin signaling transduction pathway.